Trials / Completed
CompletedNCT00326950
Phase I Clinical Study of E7389
Phase I Clinical Study of E7389 in Patients With Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to determine the dose limiting toxicity and maximum tolerated dose of E7389 in patients with solid tumors. The secondary objectives are to investigate the pharmacokinetics, safety, estimated recommended dose, and anti-tumor effects (in evaluable cases) of E7389 in patients with solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E7389 | E7389 will be administered intravenously on Days 1 and 8 of a 21 day cycle. The initial dose level will be 0.7 mg/m2, with planned dose levels of 1.0, 1.4, 2.0 mg/m2. |
Timeline
- Start date
- 2006-06-01
- Primary completion
- 2008-01-01
- Completion
- 2008-02-01
- First posted
- 2006-05-17
- Last updated
- 2012-03-08
- Results posted
- 2011-12-20
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00326950. Inclusion in this directory is not an endorsement.